Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
40.67
-0.22 (-0.54%)
Apr 29, 2026, 10:23 AM EDT - Market open
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$987,380
Profits / Employee
-$51,400
Market Cap
3.76B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
| Tango Therapeutics | 137 |
| NewAmsterdam Pharma Company | 100 |
TVTX News
- 1 day ago - Travere Therapeutics to Report First Quarter 2026 Financial Results - Business Wire
- 14 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients - Benzinga
- 15 days ago - Travere Therapeutics Transcript: Study update - Transcripts
- 15 days ago - US FDA expands approval for Travere Therapeutics' drug for rare kidney disease - Reuters
- 15 days ago - Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS - Business Wire
- 2 months ago - Travere Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire